Muscarinic binding sites in a catecholaminergic human neuroblastoma cell line.
Tyrosine hydroxylase (TH) a characteristic enzyme activity for the catecholaminergic clonal cell line LA-N-1 and choline acetyltransferase (ChAT) a characteristic enzyme activity for the cholinergic clonal cell line LA-N-2 were previously shown to be increased in these cells exposed to 10(-5) M retinoic acid (RA) as differentiating agent. An investigation of the receptor characteristics suggests a complementarity between the two cell lines. The binding of QNB, a muscarinic ligand, was undetectable with the LA-N-2 cells but was present in the LA-N-1 cells and possessed a kD of 1.8 nM and 2.2 nM and a Bmax of 0.56 and 0.68 for control and RA grown cells respectively. There was a gradual increase in QNB binding to LA-N-1 cells from 2 days in vitro (DIV) until 6 DIV in both control and RA grown cells. An IC50 of 2.5 x 10(-8) M and 0.9 x 10(-8) M for atropine inhibition was obtained for the control and RA grown cells respectively. The corresponding values for carbachol inhibition were 7 x 10(-2) M and 3 x 10(-2) M respectively. The inhibition by the agonist oxotremorine is comparable to that of carbachol and 1 mM pilocarpine inhibited the binding by 21%. QNB binding showed a low affinity for pirenzepine and for AF-DX-116 but was inhibited with a rather high affinity by 4-DAMP (IC50:110 microM) thus suggesting the presence of an M3 receptor. Acetylcholine (100 microM) plus eserine (50 microM) and BW284c55 (1 microM), an acetylcholinesterase inhibitor, reduced the binding of QNB by approximately 25%.(ABSTRACT TRUNCATED AT 250 WORDS)
Sorrentino
G
G
Department of Biochemistry and Molecular Biology, University of Manitoba, Winnipeg, Canada.
Singh
I N
IN
Hubsch
A
A
Kanfer
J N
JN
Mykita
S
S
Massarelli
R
R
D001665:Binding Sites / Q000502:physiology; D002038:Bungarotoxins / Q000378:metabolism; D002395:Catecholamines / Q000502:physiology*; D002454:Cell Differentiation / Q000502:physiology; D000242:Cyclic AMP / Q000032:analysis; D006801:Humans; D006868:Hydrolysis; D009447:Neuroblastoma / Q000378:metabolism; D009474:Neurons / Q000378:metabolism*; D010716:Phosphatidylinositols / Q000378:metabolism; D011813:Quinuclidinyl Benzilate / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000032:analysis* / Q000187:drug effects; D015290:Second Messenger Systems / Q000187:drug effects; D014407:Tumor Cells, Cultured
D002038:Bungarotoxins; D002395:Catecholamines; D010716:Phosphatidylinositols; D011976:Receptors, Muscarinic; D011813:Quinuclidinyl Benzilate; D000242:Cyclic AMP